In a study published in Science Translational Medicine, scientists report success using a lower amplitude, high-frequency alternating current at 100-200 Hz to stop the arrhythmia in the laboratory. They say this approach also may prove to be less painful for patients because of the lower amplitude and different frequency range than what is used for standard defibrillator shocks.
While more testing is needed in animal models, the researchers are optimistic that their work may lead to a new approach to shock the human heart back to a normal rhythm.
Related Articles on Johns Hopkins:
Study Reveals Rise in Prostate Biopsy-Related Complications, Readmissions
Basic Infection Prevention Saved Children’s Hospitals $104M Over 5 Yrs
Johns Hopkins to Partner With MX.com to Offer Care Protocols, Other Tools
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
